**Author details**

Muhtashim Mian and Habib Rehman Khan\* London Health Sciences Centre, London, Canada Schulich School of Medicine and Dentistry, University of Western Ontario

\*Address all correspondence to: habib.khan@lhsc.on.ca

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Conduction System Disorders Associated with Valvular Heart Disease and Interventions DOI: http://dx.doi.org/10.5772/intechopen.108558*

## **References**

[1] Iung B, Vahanian A. Epidemiology of valvular heart disease in the adult. Nature Reviews. Cardiology. 2011;**8**:162-172

[2] Sick Sinus Syndrome: A Review. Available from: https://www.aafp.org/ pubs/afp/issues/2013/0515/p691.html. [Accessed: July 17, 2022]

[3] Cheng S, Keyes MJ, Larson MG, McCabe EL, Newton-Cheh C, Levy D, et al. Long-term outcomes in individuals with prolonged PR interval or firstdegree atrioventricular block. JAMA. 2009;**301**:2571-2577

[4] Nikoo MH, Aslani A, Jorat MV. LBBB: State-of-the-art criteria. International Cardiovascular Research Journal. 2013;**7**:39

[5] Francia P, Balla C, Paneni F, Volpe M. Left bundle-branch block— Pathophysiology, prognosis, and clinical management. Clinical Cardiology. 2007;**30**:110-115

[6] Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and Antiarrhythmia devices: Summary article. A report of the American College of Cardiology/ American Heart Association task force on practice guidelines (ACC/AHA/ NASPE committee to update the 1998 pacemaker guidelines). Circulation. 2002;**106**:2145-2161

[7] Kourkoveli P, Spargias K, Hahalis G. Perspective open access • TAVR in 2017-what we know? What to expect? Journal of Geriatric Cardiology. 2018;**15**:55-60

[8] Kolte D, Vlahakes GJ, Palacios IF, Sakhuja R, Passeri JJ, Inglessis I, et al. Transcatheter versus surgical aortic valve replacement in low-risk patients. Journal of the American College of Cardiology. 2019;**74**:1532-1540

[9] Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: An updated meta-analysis. European Heart Journal. 2019;**40**:3143-3153

[10] Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC/AHA guideline for the Management of Patients with Valvular Heart Disease: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation, 2021; 143: E72–E227.

[11] Lee HA, Chou AH, Wu VCC, Chen DY, Lee HF, Lee KT, et al. Balloonexpandable versus self-expanding transcatheter aortic valve replacement for bioprosthetic dysfunction: A systematic review and meta-analysis. PLoS One. 2020;**15**:e0233894

[12] van Belle E, Vincent F, Labreuche J, Auffret V, Debry N, Lefèvre T, et al. Balloon-expandable versus selfexpanding Transcatheter aortic valve replacement. Circulation. 2020;**141**:243-259

[13] Ullah W, Zahid S, Zaidi SR, Sarvepalli D, Haq S, Roomi S, et al. Predictors of permanent pacemaker implantation in patients undergoing Transcatheter aortic valve replacement - a systematic review and meta-analysis. Journal of the American Heart Association. 2021;**10**:20906

[14] Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, et al. Predictors and clinical outcomes of permanent pacemaker implantation

after transcatheter aortic valve replacement: The PARTNER (placement of AoRtic TraNscathetER valves) trial and registry. JACC. Cardiovascular Interventions. 2015;**8**:60-69

[15] Kiani S, Kamioka N, Black GB, Lu MLR, Lisko JC, Rao B, et al. Development of a risk score to predict new pacemaker implantation after Transcatheter aortic valve replacement. JACC. Cardiovascular Interventions. 2019;**12**:2133-2142

[16] Limongelli G, Ducceschi V, D'Andrea A, Renzulli A, Sarubbi B, de Feo M, et al. Risk factors for pacemaker implantation following aortic valve replacement: A single Centre experience. Heart. 2003;**89**:901-904

[17] Bagur R, Manazzoni JM, Dumont É, Doyle D, Perron J, Dagenais F, et al. Permanent pacemaker implantation following isolated aortic valve replacement in a large cohort of elderly patients with severe aortic stenosis. Heart. 2011;**97**:1687-1694

[18] van Mieghem NM, Head SJ, de Jong W, van Domburg RT, Serruys PW, de Jaegere PP, et al. Persistent annual permanent pacemaker implantation rate after surgical aortic valve replacement in patients with severe aortic stenosis. The Annals of Thoracic Surgery. 2012;**94**:1143-1149

[19] Meco M, Montisci A, Miceli A, Panisi P, Donatelli F, Cirri S, et al. Sutureless perceval aortic valve versus conventional stented bioprostheses: Meta-analysis of postoperative and midterm results in isolated aortic valve replacement. Journal of the American Heart Association. 2018;**7**:e006091. DOI: 10.1161/JAHA.117.006091

[20] Hurley ET, O'Sullivan KE, Segurado R, Hurley JP. A meta-analysis examining differences in short-term outcomes between Sutureless and conventional aortic valve prostheses. Innovations (Phila). 2015;**10**:375-382

[21] Phan K, Tsai Y-C, Niranjan N, Bouchard D, Carrel TP, Dapunt OE, et al. Sutureless aortic valve replacement: A systematic review and meta-analysis. Annals of Cardiothoracic Surgery. 2015;**4**:e46

[22] Muneretto C, Solinas M, Folliguet T, di Bartolomeo R, Repossini A, Laborde F, et al. Sutureless versus transcatheter aortic valves in elderly patients with aortic stenosis at intermediate risk: A multi-institutional study. The Journal of Thoracic and Cardiovascular Surgery. 2022;**163**:925-935.e5

[23] Muneretto C, Alfieri O, Cesana BM, Bisleri G, de Bonis M, di Bartolomeo R, et al. A comparison of conventional surgery, transcatheter aortic valve replacement, and sutureless valves in "real-world" patients with aortic stenosis and intermediate- to high-risk profile. The Journal of Thoracic and Cardiovascular Surgery. 2015;**150**:1570-1579

[24] Abdel-Wahab M, Fujita B, Frerker C, Bauer T, Beckmann A, Bekeredjian R, et al. Transcatheter versus rapid-deployment aortic valve replacement: A propensity-matched analysis from the German aortic valve registry. Cardiovascular Interventions. 2020;**13**:2642-2654

[25] Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, et al. Outcomes 2 years after Transcatheter aortic valve replacement in patients at low surgical risk. Journal of the American College of Cardiology. 2021;**77**:1149-1161

[26] Berdajs D, Schurr UP, Wagner A, Seifert B, Turina MI, Genoni M. Incidence and pathophysiology of atrioventricular block following mitral valve replacement and ring annuloplasty. European Journal of Cardio-Thoracic Surgery. 2008;**34**(1): 55-61. DOI: 10.1016/j.ejcts.2008.03.051

*Conduction System Disorders Associated with Valvular Heart Disease and Interventions DOI: http://dx.doi.org/10.5772/intechopen.108558*

[27] Meimoun P, Zeghdi R, D'Attelis N, Berrebi A, Braunberger E, Deloche A, et al. Frequency, predictors, and consequences of atrioventricular block after mitral valve repair. The American Journal of Cardiology. 2002;**89**:1062-1066

[28] Leyva F, Qiu T, Mcnulty D, Evison F, Marshall H, Gasparini M. Long-term requirement for pacemaker implantation after cardiac valve replacement surgery. Heart Rhythm. 2017;**14, 4**:529-534. DOI: 10.1016/j. hrthm.2016.11.029

[29] Merin O, Ilan M, Oren A, Fink D, Deeb M, Bitran D, et al. Permanent pacemaker implantation following cardiac surgery: Indications and longterm follow-up. Pacing and Clinical Electrophysiology. 2009;**32**:7-12

[30] Ghauri H, Iqbal R, Ahmed S, Ashraf A, Khan MSQ, Malik J, et al. Predictors of permanent pacemaker insertion after mitral valve replacement: A systematic review. PACE - Pacing and Clinical Electrophysiology. 2022;**45**:681-687

[31] Erinne I, Theertham AK, Maleki K, Chen C, Russo M, Hakeem A. Complete atrioventricular block: A rare complication of MitraClip implantation. JACC Case Reports. 2021;**3**:772-777

[32] Alkhouli M, Alqahtani F, Aljohani S. Transcatheter mitral valve replacement: An evolution of a revolution. Journal of Thoracic Disease. 2017;**9**:S668-S672

[33] Bapat V, Rajagopal V, Meduri C, Farivar RS, Walton A, Duffy SJ, et al. Early experience with new Transcatheter mitral valve replacement. Journal of the American College of Cardiology. 2018;**71**:12-21

[34] Webb JG, Murdoch DJ, Boone RH, Moss R, Attinger-Toller A, Blanke P, et al. Percutaneous Transcatheter mitral valve replacement: First-in-human

experience with a new Transseptal system. Journal of the American College of Cardiology. 2019;**73**:1239-1246

[35] Makkar R, O'Neill W, Whisenant B, Guerrero M, Feldman T, Rihal C, et al. TCT-8 updated 30-day outcomes for the U.S. early feasibility study of the SAPIEN M3 transcatheter mitral valve replacement system. Journal of the American College of Cardiology. 2019;**74**:B8

[36] Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. Journal of the American College of Cardiology. 2004;**43**:405-409

[37] Dreyfus J, Ghalem N, Garbarz E, Cimadevilla C, Nataf P, Vahanian A, et al. Timing of referral of patients with severe isolated tricuspid valve regurgitation to surgeons (from a French Nationwide database). The American Journal of Cardiology. 2018;**122**:323-326

[38] Riesenhuber M, Spannbauer A, Gwechenberger M, Pezawas T, Schukro C, Stix G, et al. Pacemaker lead-associated tricuspid regurgitation in patients with or without pre-existing right ventricular dilatation. Clinical Research in Cardiology. 2021;**110**:884-894

[39] Hahn RT, Kodali S, Fam N, Bapat V, Bartus K, Rodés-Cabau J, et al. Early multinational experience of Transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation. JACC. Cardiovascular Interventions. 2020;**13**:2482-2493

[40] Kar S, Noureddin N, Aboulhosn J, Mahmzi Y, Coluzzi A, Tobis J, et al. Rapid pacing using the guidewire during Transcatheter tricuspid valve in valve implantation. Journal of Structural Heart Disease. 2017;**3**: 157-162

[41] Bradshaw PJ, Stobie P, Knuiman MW, Briffa TG, Hobbs MST. Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population. Open Heart. 2014;**1**:e000177. DOI: 10.1136/ openhrt-2014-000177

[42] Verma N, Dandamudi S, Goldberger JJ, Lip GYH, Huffman MD. Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block. Cochrane Database of Systematic Reviews. 2004;**2004**:CD003710. DOI: 10.1002/14651858.CD003710.PUB2

[43] Toff WD, Camm AJ, Douglas J, Skehan MB. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. The New England Journal of Medicine. 2005;**353**:145-155. DOI: 101056/ NEJMoa042283

[44] Vaidya VR, Dai M, Asirvatham SJ, Rea RF, Thome TM, Srivathsan K, et al. Real-world experience with leadless cardiac pacing. Pacing and Clinical Electrophysiology. 2019;**42**:366-373

[45] Ngo L, Nour D, Denman RA, Walters TE, Haqqani HM, Woodman RJ, et al. Safety and efficacy of leadless pacemakers: A systematic review and meta-analysis. Journal of the American Heart Association. 2021;**10**:19212

[46] Duray GZ, Ritter P, El-Chami M, Narasimhan C, Omar R, Tolosana JM, et al. Long-term performance of a transcatheter pacing system: 12-month results from the Micra Transcatheter pacing study. Heart Rhythm. 2017;**14**:702-709

[47] McIntosh RA, Ansari MI, Moon J, Khan HR. Delivery of cardiac resynchronization therapy via the left inferior phrenic vein: A case report. European Heart Journal - Case Reports. 2019:3, ytz144. DOI: 10.1093/ ehjcr/ytz144

[48] Kuo-Wei Chiang C, Ka-Bo Chan W, So A, Yee R, Khan H. Utilizing preprocedural imaging and active fixation lead in cardiac resynchronization therapy device upgrade for persistent left superior vena cava. Heart Rhythm Case Reports. 2021;**8**:50-53

[49] Kanawati J, Kanawati AJ, Rowe MK, Khan H, Chan WK, Yee R. Utility of 3-D printing for cardiac resynchronization device implantation in congenital heart disease. Heart Rhythm Case Reports. 2020;**6**:754-756

[50] Bleeker GB, Schalij MJ, Molhoek SG, Verwey HF, Holman ER, Boersma E, et al. Relationship between QRS duration and left ventricular dyssynchrony in patients with end-stage heart failure. Journal of Cardiovascular Electrophysiology. 2004;**15**:544-549

[51] Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England Journal of Medicine. 2009;**352**:1539-1549. DOI: 101056/ NEJMoa050496

[52] Nam EFT Jr, Tracy CM, Epstein AE, Chair V, Darbar D, et al. ACCF/AHA/ HRS focused update ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2012;**126**:1784-1800

[53] Ousdigian KT, Borek PP, Koehler JL, Heywood JT, Ziegler PD, Wilkoff BL. The epidemic of inadequate biventricular pacing in patients with persistent or permanent atrial fibrillation and its association with

*Conduction System Disorders Associated with Valvular Heart Disease and Interventions DOI: http://dx.doi.org/10.5772/intechopen.108558*

mortality. Circulation. Arrhythmia and Electrophysiology. 2014;**7**:370-376

[54] Mustafa U, Atkins J, Mina G, Dawson D, Vanchiere C, Duddyala N, et al. Outcomes of cardiac resynchronisation therapy in patients with heart failure with atrial fibrillation: A systematic review and meta-analysis of observational studies. Open Heart. 2019;**6**:e000937

[55] Lin J, Dai Y, Wang H, Li Y, Chen K, Zhang S. A comparison of left bundle branch pacing with his bundle pacing in a patient with heart failure and left bundle branch block. Heart Rhythm Case Reports. 2020;**6**:293

[56] Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, et al. Clinical outcomes of his bundle pacing compared to right ventricular pacing. Journal of the American College of Cardiology. 2018;**71**:2319-2330

[57] Lewis AJM, Foley P, Whinnett Z, Keene D, Chandrasekaran B. His bundle pacing: A new strategy for physiological ventricular activation. Journal of the American Heart Association. 2019;**8**:10972

[58] Keene D, Arnold AD, Jastrzębski M, Burri H, Zweibel S, Crespo E, et al. His bundle pacing, learning curve, procedure characteristics, safety, and feasibility: Insights from a large international observational study. Journal of Cardiovascular Electrophysiology. 2019;**30**:1984-1993

[59] Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal. 2021;**42**(35):3427-3520. DOI: 10.1093/ EURHEARTJ/EHAB364

[60] Brenyo A, Goldenberg I, Barsheshet A. The downside of right ventricular apical pacing. Indian Pacing and Electrophysiology Journal. 2012;**12**:102

[61] Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. The New England Journal of Medicine. 2002;**346**:1854-1862

[62] Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate. Heart Failure. 2010;**363**:2385-2395. DOI: 101056/ NEJMoa1009540

[63] Goldenberg I, Kutyifa V, Klein HU, Cannom DS, Brown MW, Dan A, et al. Survival with cardiac-resynchronization therapy in mild heart failure. New England Journal of Medicine. 2014;**370**:1694-1701

[64] Daubert C, Behar N, Martins RP, Mabo P, Leclercq C. Avoiding nonresponders to cardiac resynchronization therapy: A practical guide. European Heart Journal. 2017;**38**:1463-1472

[65] Ali N, Shin MS, Whinnett Z. The emerging role of cardiac conduction system pacing as a treatment for heart failure. Current Heart Failure Reports. 2020;**17**:288

[66] Kanawati J, Ng ACC, Khan H, Yu C, Hyun K, Abed H, et al. Long-term follow-up of mortality and heart failure hospitalisation in patients with Intracardiac device-related tricuspid regurgitation. Heart, Lung & Circulation. 2021;**30**:692-697

[67] Beurskens NEG, Tjong FVY, de Bruin-Bon RHA, Dasselaar KJ, Kuijt WJ, Wilde AAM, et al. Impact of leadless pacemaker therapy on cardiac and atrioventricular valve function through 12 months of follow-up. Circulation. Arrhythmia and Electrophysiology.

2019;**12**:e007124. DOI: 10.1161/ CIRCEP.118.007124

[68] Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. Journal of the American College of Cardiology. 2017;**69**:2331-2341

[69] Schleifer JW, Pislaru SV, Lin G, Powell BD, Espinosa R, Koestler C, et al. Effect of ventricular pacing lead position on tricuspid regurgitation: A randomized prospective trial. Heart Rhythm. 2018;**15**:1009-1016

Section 6
